Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
Gastrointestinal (GI) cancers are a group of malignancies that globally account for a significant portion of cancer incidence and cancer-related death. Survival outcomes for esophageal, gastric, pancreatic, and hepatobiliary cancers remain poor, but new treatment paradigms are emerging with the adve...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/1/60 |
| _version_ | 1797443941701779456 |
|---|---|
| author | Hyejee Ohm Omar Abdel-Rahman |
| author_facet | Hyejee Ohm Omar Abdel-Rahman |
| author_sort | Hyejee Ohm |
| collection | DOAJ |
| description | Gastrointestinal (GI) cancers are a group of malignancies that globally account for a significant portion of cancer incidence and cancer-related death. Survival outcomes for esophageal, gastric, pancreatic, and hepatobiliary cancers remain poor, but new treatment paradigms are emerging with the advent of immune checkpoint inhibitor (ICI) therapy. This review characterizes patient-related prognostic factors that influence the response to ICI therapy. We performed an analysis of the landmark randomized clinical trials in esophageal, gastric, colorectal, hepatocellular, pancreatic, and biliary tract cancers in terms of patient demographic factors. A literature review of smaller retrospective studies investigating patient-related factors was completed. The immunological bases for these associations were further explored. The key predictive factors identified include age, sex, performance status, geography, body mass index, sarcopenia, gut microbiome, various biochemical factors, and disease distribution. |
| first_indexed | 2024-03-09T13:04:22Z |
| format | Article |
| id | doaj.art-0d5ae6f7d01d4c0b93b2a1e2d56cde3a |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T13:04:22Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-0d5ae6f7d01d4c0b93b2a1e2d56cde3a2023-11-30T21:49:41ZengMDPI AGCurrent Oncology1198-00521718-77292023-01-0130178680210.3390/curroncol30010060Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint InhibitorsHyejee Ohm0Omar Abdel-Rahman1Department of Medicine, University of Alberta, Edmonton, AB T6G 1Z2, CanadaDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, CanadaGastrointestinal (GI) cancers are a group of malignancies that globally account for a significant portion of cancer incidence and cancer-related death. Survival outcomes for esophageal, gastric, pancreatic, and hepatobiliary cancers remain poor, but new treatment paradigms are emerging with the advent of immune checkpoint inhibitor (ICI) therapy. This review characterizes patient-related prognostic factors that influence the response to ICI therapy. We performed an analysis of the landmark randomized clinical trials in esophageal, gastric, colorectal, hepatocellular, pancreatic, and biliary tract cancers in terms of patient demographic factors. A literature review of smaller retrospective studies investigating patient-related factors was completed. The immunological bases for these associations were further explored. The key predictive factors identified include age, sex, performance status, geography, body mass index, sarcopenia, gut microbiome, various biochemical factors, and disease distribution.https://www.mdpi.com/1718-7729/30/1/60GI cancerdigestive malignanciesICIsimmunotherapy |
| spellingShingle | Hyejee Ohm Omar Abdel-Rahman Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors Current Oncology GI cancer digestive malignancies ICIs immunotherapy |
| title | Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors |
| title_full | Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors |
| title_fullStr | Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors |
| title_full_unstemmed | Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors |
| title_short | Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors |
| title_sort | impact of patient characteristics on the outcomes of patients with gastrointestinal cancers treated with immune checkpoint inhibitors |
| topic | GI cancer digestive malignancies ICIs immunotherapy |
| url | https://www.mdpi.com/1718-7729/30/1/60 |
| work_keys_str_mv | AT hyejeeohm impactofpatientcharacteristicsontheoutcomesofpatientswithgastrointestinalcancerstreatedwithimmunecheckpointinhibitors AT omarabdelrahman impactofpatientcharacteristicsontheoutcomesofpatientswithgastrointestinalcancerstreatedwithimmunecheckpointinhibitors |